GLP-1 (Glucagon-Like Peptide-1) is an incretin hormone naturally produced and secreted by L-cells in the small intestine in response to food intake. Its effects on blood glucose regulation and body weight have made it a major target for type 2 diabetes and obesity drug development.
The Incretin Mechanism
GLP-1 stimulates insulin secretion from the pancreas in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and promotes satiety by acting on appetite-regulating centers in the brain. This multi-pronged mechanism produces complementary effects on blood glucose and body weight simultaneously.
Synthetic GLP-1 Receptor Agonists
Because native GLP-1 has a very short half-life (approximately 2 minutes) due to rapid degradation by the enzyme DPP-4, pharmaceutical research has focused on developing synthetic analogs with extended half-lives. These include semaglutide, liraglutide, dulaglutide, and exenatide, each engineered with structural modifications to resist enzymatic degradation.
Clinical Research Findings
Clinical trials of GLP-1 receptor agonists have demonstrated substantial improvements in glycemic control, body weight reduction ranging from 10-20% in various trials, and cardiovascular risk reduction. The LEADER trial (liraglutide) and SELECT trial (semaglutide) demonstrated cardiovascular outcome benefits beyond glucose control.
Emerging Research Areas
Recent research has explored GLP-1 receptor signaling in the brain, liver, and cardiovascular system. Emerging preclinical evidence suggests potential neuroprotective properties, with ongoing trials examining GLP-1 receptor agonists in Parkinson's disease and Alzheimer's disease.
Research Disclaimer: This article is for educational purposes only and does not constitute medical advice.